Investor Type | Firm |
Industries | BioTech • HealthTech (& Fitness) • Medical Devices (& Hospital Services) • Healthcare (& Wellness) • Pharmaceutical (& Medicine) |
Stages | Seed, Series A |
Investing | United States • Japan |
Investment Range | $100,000 - $5,000,000 |
Investment Sweet Spot | $1,500,000 |
Axil Capital is a Tokyo-based venture capital firm that specializes in investments within the biomedical and healthcare technology sectors. They focus on fostering the growth of early-stage ventures, particularly those at the seed and Series A funding stages. Their investment approach is highlighted by their dedication towards businesses that operate across a variety of healthcare-related industries, including BioTech, HealthTech and Fitness, Medical Devices and Hospital Services, Healthcare and Wellness, and Pharmaceutical and Medicine. With a global network and vast resources, Axil Capital aims to support innovative startups that show potential for significant impact and growth within the healthcare ecosystem. Their minimum investment amount is set to 100,000 USD, while the maximum they provide climbs to 5,000,000 USD. They identify their investment 'sweet spot' at 1,500,000 USD, indicating a preferred level of investment that aligns with their strategy and target portfolio profiles. The recent formation of TaiAx Life Science Fund L.P., a joint venture with Taiwania Capital, and the involvement in various funding rounds, including Series B financing, speaks to their active and strategic participation in funding rounds that help to drive the healthcare and life science industry forward. By collaborating with other entities such as a U.S. Texas-based life science venture studio and investing in a diverse set of companies such as LinqMed, Y4, MabGenesis, Pulmotect, CynosBio, and Jolly Good, Axil Capital not only diversifies its portfolio but also contributes to the advancement of medical and healthcare technologies.